Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

R-Pharm enters into an agreement with Bristol-Myers Squibb for Reyataz

Nov. 21, 2014

Theravectys updates on phase I/II trial of lentiviral vector HIV vaccine

Nov. 20, 2014

Vacc-4x and lenalidomide increase CD4 count in phase I/II trial in patients with HIV infection

Nov. 18, 2014

Merck & Co. patent reports new HIV integrase inhibitors

Nov. 10, 2014

Gilead files NDA for elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for HIV

Nov. 7, 2014

Gilead Sciences begins phase Ib study of GS-9883

Nov. 5, 2014

Bristol-Myers Squibb reports new HIV integrase inhibitors

Oct. 30, 2014

Bristol-Myers Squibb patents new HIV integrase inhibitors

Oct. 28, 2014

Bristol-Myers Squibb prepares novel agents for HIV infection

Oct. 27, 2014

Potency of a novel NRTI against drug-resistant retroviruses

Oct. 16, 2014

Popular Stories

Today's news in brief
BioWorld
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...